Our News Bureau
Mumbai

US-India Chamber of Commerce (USAIC), a bilateral Chamber of Commerce is organising the annual US-India BioPharma and Healthcare Summit on May 11, 2012 at President’s Ballroom, Hyatt Regency Cambridge, Massachusetts, US. The event will see a congregation of biopharma, medical devices, healthcare companies, venture capitalists, policy makers and academia from the US, Europe and India.

Pre summit strategy sessions, by invitation only, will discuss external research strategies and industry-academic research partnerships. This year’s theme is ‘Delivering affordable innovation through global partnerships.’ The disease area chosen for focus is oncology.

Panel discussions during the Summit will cover subtopics like Drug Discovery and Collaborative Research; Restructuring R&D to Maximise Productivity and Innovation; Therapeutic Area-Oncology: Science, Research Trends, Investor Perspective & Market Opportunities; R&D Models: Lessons learned for BioPharma; Industry-Academic Partnerships; Clinical Research – Opportunities and Challenges; IP & Regulatory issues; Emerging Markets Opportunities and Strategies; Funding innovation, Cross Border Investments, Licensing and M&A trends in the BioPharma & Healthcare. Annual R&D budget of the Advisory Board members is more than $25 billion.

The advisory board members of the USAIC, include big names like Martin Mackay, President – R&D, AstraZeneca; Dr Paul Stoffels, Group Chairman of Global Pharma and R&D, Johnson & Johnson; Dr MK Bhan, Secretary to the Government of India, Department of Biotechnology; Hari S Bhartia, Co-Chairman, Jubilant Life Sciences; Dr Elias Zerhouni, President - Global R&D, Sanofi; Dr Mikael Dolsten, President Worldwide R&D, Pfizer; Prof Nirmal Kumar Ganguly, Chairman, JIPMER Pondicherry & Ex Director General ICMR; Dr John Leonard, Sr VP Pharma R&D, Abbott; Kiran Mazumdar Shaw, CMD, Biocon; Dr KV Subramaniam, CEO, Reliance Life Sciences; Dr Naresh Trehan, Chairman, Medanta - the Medicity; Dr Michael Rosenblatt, Executive VP and CMO, Merck & Co; Dr Allen M Spiegel, Dean, Albert Einstein College of Medicine, Yeshiva University; Dr Peter Mueller, Executive VP, Global R&D & CSO, Vertex Pharmaceuticals; Dr Raju Kucherlapati, Paul C Cabot Professor, Department of Genetic, Harvard Medical School, Dr Barry R Bloom, Professor & Fast Dean, Harvard School of Public Health.

Boston Consulting Group is the Knowledge Partner and will release a white paper at the Summit. For more details on the Summit contact Karun Rishi, President, USAIC, at info@usaindiachamber.org

EXPRESS PHARMA

February 1-15, 2012

www.expresspharmaonline.com